BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21546871)

  • 1. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
    Kim MK; Yoon BS; Park H; Seong SJ; Chung HH; Kim JW; Kang SB
    Int J Gynecol Cancer; 2011 May; 21(4):673-7. PubMed ID: 21546871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
    Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
    Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
    Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
    Giannopoulos T; Butler-Manuel S; Tailor A
    Gynecol Oncol; 2004 Dec; 95(3):762-4. PubMed ID: 15582001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
    Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
    Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
    Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
    Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved.
    Perri T; Korach J; Gotlieb WH; Beiner M; Meirow D; Friedman E; Ferenczy A; Ben-Baruch G
    Int J Gynecol Cancer; 2011 Jan; 21(1):72-8. PubMed ID: 21178572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.
    Nucera G; Mandato VD; Gelli MC; Palomba S; La Sala GB
    Gynecol Endocrinol; 2013 Mar; 29(3):219-21. PubMed ID: 23153053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative treatment of early endometrial cancer: preliminary results of a pilot study.
    Laurelli G; Di Vagno G; Scaffa C; Losito S; Del Giudice M; Greggi S
    Gynecol Oncol; 2011 Jan; 120(1):43-6. PubMed ID: 21040953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
    Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
    Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.